Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha
- PMID: 17761207
- DOI: 10.1016/j.virol.2007.07.024
Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha
Abstract
Western equine encephalitis virus (WEEV) is a positive-sense, single-stranded RNA virus which is transmitted to equines and humans through mosquito bites. WEEV infects the central nervous system with severe complications and even death. There are no human vaccine and antiviral drugs. We investigated whether adenovirus-mediated expression of interferon alpha could be used for pre- and post-exposure protection against a lethal WEEV challenge in mice. A human adenoviral vector (Ad5-mIFNalpha) expressing mouse interferon alpha was constructed. We found that Ad5-mIFNalpha provided 100% protection against various WEEV strains in mice after a single intramuscular inoculation at 24 h, 48 h or 1 week before the challenge. When given as a single inoculation at 6 h after the challenge, Ad5-mIFNalpha delayed the progress of WEEV infection and provided about 60% protection. Our findings suggest that adenovirus-mediated expression of interferon alpha can be an alternative approach for the prevention and treatment of WEEV infection.
Similar articles
-
Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus.Vaccine. 2007 Aug 14;25(33):6271-6. doi: 10.1016/j.vaccine.2007.05.054. Epub 2007 Jun 14. Vaccine. 2007. PMID: 17630056
-
Envelope protein E1 as vaccine target for western equine encephalitis virus.Vaccine. 2011 Jan 17;29(4):813-20. doi: 10.1016/j.vaccine.2010.11.009. Epub 2010 Dec 3. Vaccine. 2011. PMID: 21084062
-
Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine.Vaccine. 2007 May 30;25(22):4368-75. doi: 10.1016/j.vaccine.2007.03.042. Epub 2007 Apr 11. Vaccine. 2007. PMID: 17467858
-
Efficacy of DNA vaccination against western equine encephalitis virus infection.Vaccine. 2005 Mar 18;23(17-18):2280-3. doi: 10.1016/j.vaccine.2005.01.032. Vaccine. 2005. PMID: 15755611
-
Immunological evaluation of Escherichia coli expressed E2 protein of Western equine encephalitis virus.Virus Res. 2007 Sep;128(1-2):26-33. doi: 10.1016/j.virusres.2007.03.030. Epub 2007 May 11. Virus Res. 2007. PMID: 17499379
Cited by
-
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.Br J Pharmacol. 2010 Oct;161(4):721-48. doi: 10.1111/j.1476-5381.2010.00939.x. Br J Pharmacol. 2010. PMID: 20860656 Free PMC article. Review.
-
Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.Future Virol. 2011 May;6(5):615-631. doi: 10.2217/fvl.11.33. Future Virol. 2011. PMID: 21765859 Free PMC article.
-
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.Sci Transl Med. 2012 Oct 31;4(158):158ra146. doi: 10.1126/scitranslmed.3004582. Sci Transl Med. 2012. PMID: 23115355 Free PMC article.
-
Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Sci Rep. 2017 Jun 22;7(1):4099. doi: 10.1038/s41598-017-03910-7. Sci Rep. 2017. PMID: 28642489 Free PMC article.
-
Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201).PLoS One. 2011;6(10):e26330. doi: 10.1371/journal.pone.0026330. Epub 2011 Oct 13. PLoS One. 2011. PMID: 22022603 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical